Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis
Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease
Objective: To determine the validity of the Parkinson’s disease (PD) home diary for quantification of motor states in patients with advanced PD and motor fluctuations.…Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of the glycine transporter 1 (GlyT1) in brain areas implicated in parkinsonism and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine…Prevalence of Movement Disorders After Acute Stroke: a Large Prospective Cohort Stroke Study
Objective: To ascertain the prevalence of acute post-stroke movement disorders (PSMD) in a prospective cohort of acute stroke patients. Background: Post-stroke movement disorders can occur…Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…Oro-bucco-lingual dyskinesia as a side effect of methotrexate therapy
Objective: to demonstrate association between the tardive dyskinesia and methotrexate therapy. Background: Dystonia is found among patients taking methotrexate. However, methotrexate and tardive oro-bucco-lingual dyskinesia…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…Amantadine Delayed Release/Extended Release Capsules Reduce the Proportion of the Day Spent in “BAD” Time (ON with Troublesome Dyskinesia or OFF): Analysis of Phase 3 Trial Data
Objective: To evaluate the effect of treatment with amantadine delayed release/extended release (AMT DR/ER) vs. placebo on the proportion of the waking day spent in…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 44
- Next Page »